Expert consensus on drug treatment of chronic subdural hematoma
Jianning Zhang,Chinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based Medicine,Zhou Fei,Hua Feng,Guodong Gao,Jiehe Hao,Lijun Hou,Jin Hu,Ying Huang,Baohua Jiao,Hongming Ji,Xiaochun Jiang,Dezhi Kang,Jianrong Li,Xingang Li,Jinfang Liu,Ning Liu,Xianzhi Liu,Ying Mao,Yan Qu,Wai Sang Poon,Ning Su,Tao Sun,Xiaochuan Sun,Jianjun Wang,Renzhi Wang,Junji Wei,Shuo Wang,Gangfeng Yin,Chao You,Rutong Yu,Xinguang Yu,Xianrui Yuan,Jianmin Zhang,Junyi Zhang,Shiguang Zhao,Yuanli Zhao,Zongmao Zhao,Chunlong Zhong,Xide Zhu,Xingen Zhu,Rongcai Jiang,Dong Wang,Ye Tian,Huijie Wei,Wei Quan,Chuang Gao,Shuyuan Yue,Ping Lei,Quanjun Deng,Shu Zhang,Yuan Zhou,Jian Sun,Shuo An,Yingsheng Wei,Xintong Ge
DOI: https://doi.org/10.1186/s41016-021-00263-z
2021-11-22
Abstract:Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment.